Tofé et al. [30] reported that GLP-1 RA therapy reduced HbA1c at 6 months (7.24 ± 1.45%) and at 12 months (7.29 ± 1.51%) as compared to the initial visit (8.18 ± 1.53%), p < 0.0001, in subjects with T2DM—results that are similar to our study when comparing V6M to V0M (Table 3, Table 4 and Table 5). The gene discussed is GCG; the disease is type 2 diabetes mellitus.